Loading...
Loading...
In a note out today, Oppenheimer reiterated an Overweight rating and $26 price target on Seattle Genetics
SGEN, implying significant upside from current levels.
"Based primarily on Adcetris' worldwide potential, we believe SGEN is attractive at current levels. We see the pivotal trial results for Adcetris in relapsed/refractory Hodgkin's lymphoma (
HL) and anaplastic large cell lymphoma (
ALCL) as very strong. We estimate >$400 million in worldwide peak sales of the drug in this indication. We also expect meaningful off-label penetration of Adcetris in earlier line HL, which we believe will drive peak sales of the drug considerably higher," Oppenheimer said in the note.
Shares of Seattle Genetics are down more than 5% today.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorNewsPrice TargetReiterationFDAIntraday UpdateMarketsAnalyst RatingsTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in